CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE

CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE

The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DELL'ORCO, PHILIP, C, KELLY, HENRY, ANDERSON, WATSON, NIGEL, STEPHEN, SHAH, GITA, PUNJABHAI, YOUNG, ROBERT, JOHN
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator DELL'ORCO, PHILIP, C
KELLY, HENRY, ANDERSON
WATSON, NIGEL, STEPHEN
SHAH, GITA, PUNJABHAI
YOUNG, ROBERT, JOHN
description The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP1567519A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP1567519A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP1567519A23</originalsourceid><addsrcrecordid>eNqNjLEOgjAURVkcjPoPjGV4Q4toHAk80ialJW0lMhFi6mSUBH_Df7YQPsDp3OSc3G30LUxnXS6lUBiXaESbO9GijXUVMyAZFFxqox0XqIBBJxNQQEhqE6CE0BlQo-OdDLbWpuE6XMFxKRnom17kupvOmODLUKRzERwqe5WVVnktStxHm8fwnPxh5S6KK3QFBz--ez-Nw92__KfHhmanc0YvOUv_SH4ROD3u</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE</title><source>esp@cenet</source><creator>DELL'ORCO, PHILIP, C ; KELLY, HENRY, ANDERSON ; WATSON, NIGEL, STEPHEN ; SHAH, GITA, PUNJABHAI ; YOUNG, ROBERT, JOHN</creator><creatorcontrib>DELL'ORCO, PHILIP, C ; KELLY, HENRY, ANDERSON ; WATSON, NIGEL, STEPHEN ; SHAH, GITA, PUNJABHAI ; YOUNG, ROBERT, JOHN</creatorcontrib><description>The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.</description><edition>7</edition><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050831&amp;DB=EPODOC&amp;CC=EP&amp;NR=1567519A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050831&amp;DB=EPODOC&amp;CC=EP&amp;NR=1567519A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DELL'ORCO, PHILIP, C</creatorcontrib><creatorcontrib>KELLY, HENRY, ANDERSON</creatorcontrib><creatorcontrib>WATSON, NIGEL, STEPHEN</creatorcontrib><creatorcontrib>SHAH, GITA, PUNJABHAI</creatorcontrib><creatorcontrib>YOUNG, ROBERT, JOHN</creatorcontrib><title>CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE</title><description>The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEOgjAURVkcjPoPjGV4Q4toHAk80ialJW0lMhFi6mSUBH_Df7YQPsDp3OSc3G30LUxnXS6lUBiXaESbO9GijXUVMyAZFFxqox0XqIBBJxNQQEhqE6CE0BlQo-OdDLbWpuE6XMFxKRnom17kupvOmODLUKRzERwqe5WVVnktStxHm8fwnPxh5S6KK3QFBz--ez-Nw92__KfHhmanc0YvOUv_SH4ROD3u</recordid><startdate>20050831</startdate><enddate>20050831</enddate><creator>DELL'ORCO, PHILIP, C</creator><creator>KELLY, HENRY, ANDERSON</creator><creator>WATSON, NIGEL, STEPHEN</creator><creator>SHAH, GITA, PUNJABHAI</creator><creator>YOUNG, ROBERT, JOHN</creator><scope>EVB</scope></search><sort><creationdate>20050831</creationdate><title>CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE</title><author>DELL'ORCO, PHILIP, C ; KELLY, HENRY, ANDERSON ; WATSON, NIGEL, STEPHEN ; SHAH, GITA, PUNJABHAI ; YOUNG, ROBERT, JOHN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP1567519A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2005</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>DELL'ORCO, PHILIP, C</creatorcontrib><creatorcontrib>KELLY, HENRY, ANDERSON</creatorcontrib><creatorcontrib>WATSON, NIGEL, STEPHEN</creatorcontrib><creatorcontrib>SHAH, GITA, PUNJABHAI</creatorcontrib><creatorcontrib>YOUNG, ROBERT, JOHN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DELL'ORCO, PHILIP, C</au><au>KELLY, HENRY, ANDERSON</au><au>WATSON, NIGEL, STEPHEN</au><au>SHAH, GITA, PUNJABHAI</au><au>YOUNG, ROBERT, JOHN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE</title><date>2005-08-31</date><risdate>2005</risdate><abstract>The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP1567519A2
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title CRYSTALLINE DERIVATIVES OF 2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1((1S)-1-METHYL-2-MORPHOLIN-4-YL)-2-OXOETHYL)-2-OXOPYRROLIDIN-3-YL)ETHENSULFONAMIDE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DELL'ORCO,%20PHILIP,%20C&rft.date=2005-08-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP1567519A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true